KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Interest & Investment Income (2018 - 2025)

Moderna (MRNA) has disclosed Interest & Investment Income for 8 consecutive years, with $70.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 23.08% to $70.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $314.0 million, a 26.12% decrease, with the full-year FY2025 number at $314.0 million, down 26.12% from a year prior.
  • Interest & Investment Income was $70.0 million for Q4 2025 at Moderna, down from $73.0 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $120.0 million in Q1 2024 to a low of $3.0 million in Q2 2021.
  • A 5-year average of $68.9 million and a median of $84.0 million in 2022 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 57.14% in 2021, then soared 1350.0% in 2022.
  • Moderna's Interest & Investment Income stood at $7.0 million in 2021, then soared by 1142.86% to $87.0 million in 2022, then rose by 18.39% to $103.0 million in 2023, then decreased by 11.65% to $91.0 million in 2024, then dropped by 23.08% to $70.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Interest & Investment Income are $70.0 million (Q4 2025), $73.0 million (Q3 2025), and $81.0 million (Q2 2025).